Checking Alzheimer's Antibody Brain Uptake: Why Receptor Binding Tests Matter
A University of Michigan brain-shuttle study found that antibody candidates with similar early brain levels could diverge markedly by day seven, underscoring the need for careful early testing. The author discusses Roche's PET imaging approach for its Alzheimer's antibody trontinemab, which separately tracks antibody distribution and amyloid plaque changes. The Michigan team's CD98hc shuttle antibody initially bound human and monkey receptors but not the mouse version, so they screened variants across all three species using surface plasmon resonance. The piece recommends comparing antibodies against consistently prepared amyloid fibrils and including control antibodies to avoid misreading binding results. It concludes by noting that instrument design and sample volume requirements matter for labs running smaller-scale assays.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in